Meropenem and Psychomotor hyperactivity - a phase IV clinical study of FDA data
Summary:
Psychomotor hyperactivity is reported as a side effect among people who take Meropenem (meropenem), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Vancomycin, and have Pain.
The phase IV clinical study analyzes which people have Psychomotor hyperactivity when taking Meropenem. It is created by eHealthMe based on reports of 33,250 people who have side effects when taking Meropenem from the FDA, and is updated regularly.
What is Meropenem?
Meropenem has active ingredients of meropenem. eHealthMe is studying from 33,295 Meropenem users. Check the latest studies of Meropenem.
What is Psychomotor hyperactivity?
Psychomotor hyperactivity (feelings of extreme restlessness) is found to be associated with 887 drugs and 1,101 conditions by eHealthMe. Check the latest studies of Psychomotor hyperactivity.
33,250 people reported to have side effects when taking Meropenem.
Among them, 20 people (0.06%) have Psychomotor hyperactivity.

Among these 20 people:
How long have people been on Meropenem when they have Psychomotor hyperactivity? *
- < 1 month: 100 %
- 1 - 6 months: 0.0 %
- 6 - 12 months: 0.0 %
- 1 - 2 years: 0.0 %
- 2 - 5 years: 0.0 %
- 5 - 10 years: 0.0 %
- 10+ years: 0.0 %
What is the gender of people who have Psychomotor hyperactivity when taking Meropenem? *
- female: 65 %
- male: 35 %
What is the age of people who have Psychomotor hyperactivity when taking Meropenem? *
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 15 %
- 30-39: 30 %
- 40-49: 0.0 %
- 50-59: 35 %
- 60+: 20 %
What are other drugs people take besides Meropenem? *
- Vancomycin: 9 people, 45.00%
- Lorazepam: 6 people, 30.00%
- Risperidone: 6 people, 30.00%
- Acetylcysteine: 5 people, 25.00%
- Valproic Acid: 5 people, 25.00%
- Baclofen: 5 people, 25.00%
- Budesonide: 5 people, 25.00%
- Sertraline: 5 people, 25.00%
- Diazepam: 5 people, 25.00%
- Fluconazole: 5 people, 25.00%
What are other side effects people have besides Psychomotor hyperactivity? *
- Fever: 10 people, 50.00%
- Dyspnea (difficult or laboured breathing): 9 people, 45.00%
- Confusional State: 6 people, 30.00%
- Hypotension (abnormally low blood pressure): 6 people, 30.00%
- Insomnia (sleeplessness): 5 people, 25.00%
- Neuroleptic Malignant Syndrome (a life-threatening neurological disorder most often caused by an adverse reaction to neuroleptic or antipsychotic agents): 5 people, 25.00%
- Tremor (trembling or shaking movements in one or more parts of your body): 4 people, 20.00%
- Stress And Anxiety: 4 people, 20.00%
- Abdominal Pain: 4 people, 20.00%
- Sedation: 4 people, 20.00%
What are the existing conditions these people have? *
- Pain: 5 people, 25.00%
- Respiratory Tract Infection: 4 people, 20.00%
- Viral Infection: 3 people, 15.00%
- Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 15.00%
- High Blood Cholesterol: 3 people, 15.00%
- Fabry's Disease (build up of a particular type of fat, called globotriaosylceramide, in the body's cells): 3 people, 15.00%
- Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 3 people, 15.00%
- Seizures (abnormal excessive or synchronous neuronal activity in the brain): 3 people, 15.00%
- Bacterial Infection: 3 people, 15.00%
- Anaemia (lack of blood): 3 people, 15.00%
* Approximation only. Some reports may have incomplete information.
Do you take Meropenem and have Psychomotor hyperactivity?
- Check whether Psychomotor hyperactivity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Meropenem:
- Meropenem (33,295 reports)
Psychomotor hyperactivity treatments and more:
- Psychomotor hyperactivity (20,459 reports)
How severe was Psychomotor hyperactivity and when was it recovered:
Expand to all the drugs that have ingredients of meropenem:
Sub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Meropenem:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Psychomotor hyperactivity:
- Psychomotor hyperactivity (887 drugs)
Browse all the conditions that are associated with Psychomotor hyperactivity:
- Psychomotor hyperactivity (1,101 conditions)
Related publications that referenced our studies
- Erden M, Gulcan E, Bilen A, Bilen Y, Uyanik A, Keles M, "Pancytopen? a and Seps? s due to Meropenem: A Case Report", Tropical Journal of Pharmaceutical Research, 2013 Jan .
- Erden M, Gulcan E, Bilen A, Bilen Y, Uyanik A, Keles M, "Pancytopen? a and Seps? s due to Meropenem: A Case Report", Tropical Journal of Pharmaceutical Research, 2013 Jan .
How the study uses the data?
The study uses data from the FDA. It is based on meropenem (the active ingredients of Meropenem) and Meropenem (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Carboplatin and Memory Impairment for Men aged 20-29 - a second ago
- Carboplatin and Memory Aids for Men aged 20-29 - a second ago
- Carboplatin and Long-Term Memory Loss for Men aged 20-29 - 2 seconds ago
- Carboplatin and Sudden Memory Loss for Men aged 20-29 - 2 seconds ago
- Carboplatin and Temporal Memory Loss for Men aged 20-29 - 2 seconds ago
- Carboplatin and Short-Term Memory Loss for Men aged 20-29 - 2 seconds ago
- Carboplatin and Loss Of Memory for Men aged 20-29 - 3 seconds ago
- Carboplatin and Impaired Memory for Men aged 20-29 - 3 seconds ago
- Carboplatin and Forgetfulness for Men aged 20-29 - 3 seconds ago
- Carboplatin and Amnesia for Men aged 20-29 - 4 seconds ago